DBV Technologies Completes Concurrent Public Offerings

Boston – November 6, 2014 – Cooley advised the underwriters on DBV Technologies' concurrent $106.4 million initial public offering and $28.3 million secondary public offering on Euronext.

DBV Technologies S.A. is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The company trades on The NASDAQ Global Market under the symbol "DBVT" and on Euronext under the symbol "DVB."

Citigroup Global Markets Inc., Leerink Partners LLC and Bryan, Garnier & Co. acted as joint global coordinators and joint book-running managers of the global offering.

The Cooley corporate and securities team advising the underwriters included partners Marc Recht, Nicole Brookshire, Div Gupta and Barbara Kosacz, special counsel Brian Leaf and associates Michael Kanatake, Anna Jarosinski, Tamim Bazzi, Danielle Gershowitz and Andrew Totman.

Critical support was provided by partner Natasha Leskovsek, special counsel Phil Mitchell and associate Leah Roffman (health care and life sciences regulatory); partner Jeremy Naylor (tax); and special counsel Cynthia Kozakiewicz and associate Scott Weston (intellectual property).

Thus far in 2014, Cooley has advised on more than 90 completed public offerings including 46 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has 800 lawyers across 11 offices in the United States and China.